Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Karen L. Thomsen"'
Publikováno v:
BMC Gastroenterology, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Patients with inflammatory bowel disease (IBD) present with reduced serum insulin-like growth factor I (IGF-I). Anti-inflammatory treatment with prednisolone or infliximab ameliorates symptoms and increases circulating IGF-I, but
Externí odkaz:
https://doaj.org/article/4f8c23494d5443f89ddca8f0e8de8126
Autor:
Thomas H. Tranah, María-Pilar Ballester, Juan Antonio Carbonell-Asins, Javier Ampuero, Gonçalo Alexandrino, Andra Caracostea, Yolanda Sánchez-Torrijos, Karen L. Thomsen, Annarein J.C. Kerbert, María Capilla-Lozano, Manuel Romero-Gómez, Desamparados Escudero-García, Carmina Montoliu, Rajiv Jalan, Debbie L. Shawcross
Publikováno v:
Tranah, T H, Ballester, M P, Carbonell-Asins, J A, Ampuero, J, Alexandrino, G, Caracostea, A, Sánchez-Torrijos, Y, Thomsen, K L, Kerbert, A J C, Capilla-Lozano, M, Romero-Gómez, M, Escudero-García, D, Montoliu, C, Jalan, R & Shawcross, D L 2022, ' Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis ', Journal of Hepatology, vol. 77, no. 6, pp. 1554-1563 . https://doi.org/10.1016/j.jhep.2022.07.014
[Background & Aims] Hyperammonaemia is central in the pathogenesis of hepatic encephalopathy. It also has pleiotropic deleterious effects on several organ systems, such as immune function, sarcopenia, energy metabolism and portal hypertension. This s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d31b2501a63e76ce68891a3d44c8d7b1
https://doi.org/10.1016/j.jhep.2022.07.014
https://doi.org/10.1016/j.jhep.2022.07.014
Autor:
Thomas D, Sandahl, Niels K, Aagaard, Karen L, Thomsen, Thorbjørn, Grøfte, Jacob, Greisen, Jens S, Christiansen, Hendrik, Vilstrup
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 31(1)
The anabolic effects of insulin-like growth factor-I (IGF-I) may involve a decrease of hepatic nitrogen (N) clearance, but this has never been studied in humans. Patients with cirrhosis have low levels of IGF-I and might benefit from IGF-I therapy. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::afd8f5241e4838dbebe797e6291ea575
https://pubmed.ncbi.nlm.nih.gov/21040412
https://pubmed.ncbi.nlm.nih.gov/21040412
Autor:
Karen L, Thomsen, Niels K, Aagaard, Susanne S, Nielsen, Henning, Grønbaek, Niels, Jessen, Jan, Frystyk, Hendrik, Vilstrup
Publikováno v:
European journal of clinical investigation. 41(1)
The acute phase response presents a catabolic event related to increased waste of amino-N via hepatic urea synthesis despite an increased need for amino-N incorporation into acute phase proteins. In our previous studies, tumour necrosis factor-α (TN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2dc1b5e5da27eb4c88a87a534926c946
https://pubmed.ncbi.nlm.nih.gov/20731702
https://pubmed.ncbi.nlm.nih.gov/20731702